The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, China

ABSTRACT Objective This study aimed to analyze disease cost levels among colorectal cancer (CRC) patients, examining differences in disease costs between those with type 2 diabetes mellitus (T2DM) and those without T2DM while considering various demographic characteristics. Methods The study include...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhi‐xu Zhu, Yu‐xin Peng, Jing‐hong Ye, Yan Wei
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.70651
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850147131639201792
author Zhi‐xu Zhu
Yu‐xin Peng
Jing‐hong Ye
Yan Wei
author_facet Zhi‐xu Zhu
Yu‐xin Peng
Jing‐hong Ye
Yan Wei
author_sort Zhi‐xu Zhu
collection DOAJ
description ABSTRACT Objective This study aimed to analyze disease cost levels among colorectal cancer (CRC) patients, examining differences in disease costs between those with type 2 diabetes mellitus (T2DM) and those without T2DM while considering various demographic characteristics. Methods The study included respondents from colorectal cancer patients diagnosed and managed within the population‐based cancer registry system of the Shanghai Municipal Center for Disease Control and Prevention from 2020 to 2022. Diabetic colorectal cancer cases were matched with nondiabetic colorectal cancer controls using propensity scores, maintaining a 1:1 ratio between cases and controls; bias for the majority of the matched variables is below 10%. Direct, indirect, and intangible costs were estimated for study subjects. Results After propensity score matching, the analysis encompassed 376 cases of T2DM‐related CRC and 376 non‐T2DM CRC cases. The T2DM group exhibited higher direct medical costs (¥57,059.65 vs. ¥48,933.93, p < 0.05), direct nonmedical costs (¥9292.45 vs. ¥7969.35), indirect costs (¥300.13 vs. ¥241.11), intangible costs (¥3601.70 vs. ¥2631.96), and total disease costs (¥70,253.93 vs. ¥59,776.36, p < 0.05) compared to the non‐T2DM group. In Stage II CRC, direct medical costs were ¥74,008.39 for the T2DM group versus ¥57,368.84 for the non‐T2DM group. Among surgical patients, direct medical costs were ¥57,658.81 for the T2DM group versus ¥1337.00 for the non‐T2DM group, and ¥49,061.52 for the non‐T2DM surgical group versus ¥1089.00 for the non‐T2DM nonsurgical group. Conclusion Colorectal cancer imposes a substantial economic burden. Patients with CRC and concurrent T2DM experience a higher economic burden compared to nondiabetic patients. Notably, individuals with both T2DM and Stage II cancer face a significantly higher economic burden, whereas surgical patients exhibit a significantly greater disease burden than nonsurgical patients. Efforts should concentrate on primary prevention and secondary prevention to alleviate the economic burden associated with colorectal cancer.
format Article
id doaj-art-eceb64ea64e7462d859947f23327c953
institution OA Journals
issn 2045-7634
language English
publishDate 2025-02-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj-art-eceb64ea64e7462d859947f23327c9532025-08-20T02:27:39ZengWileyCancer Medicine2045-76342025-02-01144n/an/a10.1002/cam4.70651The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, ChinaZhi‐xu Zhu0Yu‐xin Peng1Jing‐hong Ye2Yan Wei3School of Public Health Fudan University Shanghai People's Republic of ChinaSchool of Public Health Fudan University Shanghai People's Republic of ChinaHongkou District Center for Disease Control and Prevention, Shanghai Hongkou District Shanghai People's Republic of ChinaSchool of Public Health Fudan University Shanghai People's Republic of ChinaABSTRACT Objective This study aimed to analyze disease cost levels among colorectal cancer (CRC) patients, examining differences in disease costs between those with type 2 diabetes mellitus (T2DM) and those without T2DM while considering various demographic characteristics. Methods The study included respondents from colorectal cancer patients diagnosed and managed within the population‐based cancer registry system of the Shanghai Municipal Center for Disease Control and Prevention from 2020 to 2022. Diabetic colorectal cancer cases were matched with nondiabetic colorectal cancer controls using propensity scores, maintaining a 1:1 ratio between cases and controls; bias for the majority of the matched variables is below 10%. Direct, indirect, and intangible costs were estimated for study subjects. Results After propensity score matching, the analysis encompassed 376 cases of T2DM‐related CRC and 376 non‐T2DM CRC cases. The T2DM group exhibited higher direct medical costs (¥57,059.65 vs. ¥48,933.93, p < 0.05), direct nonmedical costs (¥9292.45 vs. ¥7969.35), indirect costs (¥300.13 vs. ¥241.11), intangible costs (¥3601.70 vs. ¥2631.96), and total disease costs (¥70,253.93 vs. ¥59,776.36, p < 0.05) compared to the non‐T2DM group. In Stage II CRC, direct medical costs were ¥74,008.39 for the T2DM group versus ¥57,368.84 for the non‐T2DM group. Among surgical patients, direct medical costs were ¥57,658.81 for the T2DM group versus ¥1337.00 for the non‐T2DM group, and ¥49,061.52 for the non‐T2DM surgical group versus ¥1089.00 for the non‐T2DM nonsurgical group. Conclusion Colorectal cancer imposes a substantial economic burden. Patients with CRC and concurrent T2DM experience a higher economic burden compared to nondiabetic patients. Notably, individuals with both T2DM and Stage II cancer face a significantly higher economic burden, whereas surgical patients exhibit a significantly greater disease burden than nonsurgical patients. Efforts should concentrate on primary prevention and secondary prevention to alleviate the economic burden associated with colorectal cancer.https://doi.org/10.1002/cam4.70651colorectal cancereconomic burdenpropensity score matchingtype 2 diabetes mellitus
spellingShingle Zhi‐xu Zhu
Yu‐xin Peng
Jing‐hong Ye
Yan Wei
The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, China
Cancer Medicine
colorectal cancer
economic burden
propensity score matching
type 2 diabetes mellitus
title The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, China
title_full The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, China
title_fullStr The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, China
title_full_unstemmed The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, China
title_short The Economic Burden of Colorectal Cancer in Type 2 Diabetes Mellitus (T2DM) in Shanghai, China
title_sort economic burden of colorectal cancer in type 2 diabetes mellitus t2dm in shanghai china
topic colorectal cancer
economic burden
propensity score matching
type 2 diabetes mellitus
url https://doi.org/10.1002/cam4.70651
work_keys_str_mv AT zhixuzhu theeconomicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina
AT yuxinpeng theeconomicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina
AT jinghongye theeconomicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina
AT yanwei theeconomicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina
AT zhixuzhu economicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina
AT yuxinpeng economicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina
AT jinghongye economicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina
AT yanwei economicburdenofcolorectalcancerintype2diabetesmellitust2dminshanghaichina